Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial
Frías, Juan P, Guja, Cristian, Hardy, Elise, Ahmed, Azazuddin, Dong, Fang, Öhman, Peter, Jabbour, Serge ALanguage:
english
Journal:
The Lancet Diabetes & Endocrinology
DOI:
10.1016/S2213-8587(16)30267-4
Date:
September, 2016
File:
PDF, 282 KB
english, 2016